This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.75% per year. These returns cover a period from January 1, 1988 through July 7, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
PBYI Beats Q3 Earnings & Revenue Estimates, Revises '24 View, Stock Up
by Zacks Equity Research
Puma Biotechnology beats third-quarter 2024 estimates for both the top and the bottom lines. The company updates its 2024 financial guidance. Stock rallies.
Allogene's Q3 Loss Narrower Than Expected, Sales Nil
by Zacks Equity Research
ALLO's third-quarter earnings beat estimates. Devoid of marketed products, management records no sales in the quarter.
IOVA Posts Narrower-Than-Expected Q3 Loss, Amtagvi Sales Drive Top line
by Zacks Equity Research
Iovance reports better-than-expected third-quarter results. Management maintains its previously issued guidance for product revenues for full-year 2024 and 2025.
NTLA's Q3 Earnings & Revenues Beat Estimates, Pipeline in Focus
by Zacks Equity Research
Intellia's third-quarter earnings and revenues surpass estimates. The company provides updates on its pipeline candidates.
Castle Biosciences (CSTL) Is a Great Choice for 'Trend' Investors, Here's Why
by Zacks Equity Research
If you are looking for stocks that are well positioned to maintain their recent uptrend, Castle Biosciences (CSTL) could be a great choice. It is one of the several stocks that passed through our "Recent Price Strength" screen.
Castle Biosciences (CSTL) Upgraded to Strong Buy: Here's Why
by Zacks Equity Research
Castle Biosciences (CSTL) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #1 (Strong Buy).
Castle Biosciences, Inc. (CSTL) Tops Q3 Earnings and Revenue Estimates
by Zacks Equity Research
Castle Biosciences (CSTL) delivered earnings and revenue surprises of 233.33% and 9.20%, respectively, for the quarter ended September 2024. Do the numbers hold clues to what lies ahead for the stock?
United Therapeutics Q3 Earnings & Sales Beat Estimates
by Zacks Equity Research
UTHR reports better-than-expected results in third-quarter 2024 on the back of strong demand for its treprostinil medications, especially Tyvaso.
Castle Biosciences, Inc. (CSTL) Hit a 52 Week High, Can the Run Continue?
by Zacks Equity Research
Castle Biosciences (CSTL) is at a 52-week high, but can investors hope for more gains in the future? We take a look at the company's fundamentals for clues.
Insmed's Q3 Loss Wider Than Expected, Sales In Line With Estimates
by Zacks Equity Research
INSM posts wider-than-expected Q3 loss. The company plans to meet the FDA before 2024-end to discuss the possibility of an accelerated approval to expand Arikayce's label.
Merck Q3 Earnings & Sales Top, Stock Down on Lowered '24 View
by Zacks Equity Research
MRK posts better-than-expected third-quarter results. The company lowers its guidance, likely due to the soft sales performance of the Gardasil vaccines.
Summit Therapeutics Posts Wider-Than-Expected Loss in Q3, Nil Sales
by Zacks Equity Research
SMMT's third-quarter earnings miss estimates. Management also provides updates on the company's pipeline.
Liquidia Technologies, Inc. (LQDA) Expected to Beat Earnings Estimates: What to Know Ahead of Q3 Release
by Zacks Equity Research
Liquidia Technologies (LQDA) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Alkermes' Q3 Earnings & Revenues Fall Shy of Estimates, Stock Down
by Zacks Equity Research
ALKS reports weaker-than-expected third-quarter 2024 results. Net sales of proprietary products increase year over year. Shares down.
VKTX Beats on Q3 Earnings, Stock Up on Obesity Pipeline Advancements
by Zacks Equity Research
Viking Therapeutics' third-quarter earnings outpace estimates. The company plans to start a mid-stage study on its obesity pill before 2024-end.
Starboard Slams Pfizer for R&D Inefficiencies, Overpaid Acquisitions
by Zacks Equity Research
Starboard calls out PFE's board of directors to take action against the latter's management for not earning sustainable revenue returns on R&D and M&A.
Here's Why Momentum in Castle Biosciences (CSTL) Should Keep going
by Zacks Equity Research
Castle Biosciences (CSTL) could be a solid choice for shorter-term investors looking to capitalize on the recent price trend in fundamentally sound stocks. It is one of the many stocks that passed through our shorter-term trading strategy-based screen.
Castle Biosciences, Inc. (CSTL) is a Great Momentum Stock: Should You Buy?
by Zacks Equity Research
Does Castle Biosciences, Inc. (CSTL) have what it takes to be a top stock pick for momentum investors? Let's find out.
AbbVie Secures FDA Approval for Parkinson's Disease Drug Vyalev
by Zacks Equity Research
With the latest approval, ABBV's Vyalev becomes the first and only subcutaneous 24-hour infusion of levodopa-based therapy for treating advanced Parkinson's disease.
Castle Biosciences, Inc. (CSTL) Soars to 52-Week High, Time to Cash Out?
by Zacks Equity Research
Castle Biosciences (CSTL) is at a 52-week high, but can investors hope for more gains in the future? We take a look at the company's fundamentals for clues.
Strength Seen in Castle Biosciences (CSTL): Can Its 9.4% Jump Turn into More Strength?
by Zacks Equity Research
Castle Biosciences (CSTL) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price increase in the near term.
Castle Biosciences (CSTL) Upgraded to Strong Buy: Here's What You Should Know
by Zacks Equity Research
Castle Biosciences (CSTL) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #1 (Strong Buy).
Here's What Could Help Castle Biosciences (CSTL) Maintain Its Recent Price Strength
by Zacks Equity Research
Castle Biosciences (CSTL) could be a great choice for investors looking to make a profit from fundamentally strong stocks that are currently on the move. It is one of the several stocks that made it through our "Recent Price Strength" screen.
Castle Biosciences, Inc. (CSTL) Q2 Earnings and Revenues Beat Estimates
by Zacks Equity Research
Castle Biosciences (CSTL) delivered earnings and revenue surprises of 293.75% and 24.38%, respectively, for the quarter ended June 2024. Do the numbers hold clues to what lies ahead for the stock?
Intra-Cellular Therapies (ITCI) Expected to Beat Earnings Estimates: Can the Stock Move Higher?
by Zacks Equity Research
Intra-Cellular (ITCI) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.